Research / Ipamorelin

Ipamorelin

Growth Hormone & Secretagogues

โ† Back to Shop
Ipamorelin

Ipamorelin Research Information

Growth Hormone Secretagogue

For Pulsatile Growth Hormone Research

โš ๏ธ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.

๐Ÿ”ฌ What is Ipamorelin?

Ipamorelin is a synthetic 5-amino acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a potent and selective growth hormone secretagogue receptor (GHSR) agonist. It was developed as a second-generation growth hormone-releasing peptide (GHRP) to mimic the action of ghrelin, stimulating the pituitary gland to release natural growth hormone in a pulsatile manner.

Compared to earlier GHRPs, Ipamorelin offers a more favorable profile, as it triggers a clean GH pulse with minimal elevation of cortisol, prolactin, or ACTH. Ipamorelin is available in pen and freeze-dried vial formulations for research purposes.

โšก How Ipamorelin Works

Ipamorelin works through a targeted mechanism to stimulate natural growth hormone release:

๐ŸŽฏ

GHSR Agonist

Binds to growth hormone secretagogue receptor (GHSR) on pituitary somatotroph cells

๐Ÿงฌ

Pulsatile GH Release

Stimulates natural pulsatile growth hormone secretion pattern

๐Ÿ›ก๏ธ

Selective Profile

Minimal cortisol, prolactin, or ACTH elevation compared to other GHRPs

Ipamorelin can be administered alone or in combination with a GHRH analog (such as CJC-1295 or Sermorelin) for enhanced synergistic GH release.

๐Ÿ“‹ Research Applications

๐Ÿงฌ

Growth Hormone Research

Studying pulsatile GH secretion and IGF-1 elevation

๐Ÿ’ช

Muscle & Recovery

Researching muscle growth, recovery, and protein synthesis

โš–๏ธ

Metabolic Research

Investigating lipolysis, fat metabolism, and energy balance

๐Ÿงช

Combination Research

Synergistic effects with GHRH analogs (CJC-1295, Sermorelin)

๐Ÿ“Š Clinical Studies

Clinical Trial (Faccioli et al., 2025)

  • Ten women (mean age 33.9 years) with abnormal sleep patterns and low serum IGF-1 (< 200 ng/mL) were included
  • After administration of 100 mcg of Ipamorelin subcutaneously, measured by a specific and validated LC-MS/MS method
  • A typical GHS (growth hormone secretagogue) effect was detected
  • In two subjects, administration resulted in growth hormone concentrations above 35 ng/mL, reaching 38.3 ng/mL, and stable GH levels were maintained over hours
  • Women with low IGF-1 and high body mass index (BMI) were more likely to respond to Ipamorelin

Phase 1 Clinical Trial (Connexios 2009)

  • Ipamorelin was evaluated in a Phase 1 clinical trial in 2009 for potential use as a growth hormone secretagogue
  • The study established its safety profile and GH-releasing properties in humans
  • Results demonstrated that Ipamorelin effectively stimulates GH release
  • The trial was discontinued after Phase 1, likely for strategic reasons rather than safety concerns

Combination Therapy (Journal of Urology 2016)

  • A retrospective review of 14 men on combination GHRP/SERM therapy (100 mcg each, 3 times daily) showed significant IGF-1 increases
  • Mean baseline IGF-1: 159.5 ng/ml โ†’ post-treatment: 239 ng/ml (p<0.0001)
  • Mean duration of continuous GHRH/GHRP treatment was 134 days

๐Ÿ’‰ Interactive Dosing Guide

Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:

๐Ÿ–Š๏ธ Step 1: Select Your Vial Size

๐Ÿ’Š Step 2: Select Your Dose

Common research protocols: 0.05-0.3 mg per injection, 1-3 times daily

Vial Size

5mg Vial

Selected Dose

0.1 mg

Doses per Vial

50 doses

Pen Clicks

6 clicks

Volume

0.06 mL

Protocol Level

Level 2 (Standard)

Recommended Schedule

1-3 times daily - Pulsatile Protocol

โš ๏ธ Do not change your dose unless advised by a qualified professional.

๐Ÿ“‹ Protocol Level Summary

Based on research protocols: 0.05-0.3 mg per injection, 1-3 times daily.

Protocol Level Target Dose Frequency 5mg Clicks 10mg Clicks Who It\'s For
Level 1 (Starting) 0.05 mg 1-3x daily 3 clicks 1.5 clicks New users, first 2 weeks
Level 2 (Standard) 0.1 mg 1-3x daily 6 clicks 3 clicks After 2 weeks, maintenance
Level 3 (Advanced) 0.15-0.2 mg 1-3x daily 9-12 clicks 4.5-6 clicks If more response needed
Level 4 (Maximum) 0.3 mg 1-3x daily 18 clicks 9 clicks Experienced users only

โš ๏ธ Do not change your dose unless advised by a qualified professional.

๐Ÿ’‰ Vial Users (Insulin Syringe)

Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:

Vial Size

5mg vial with 3mL bac water

Dose Frequency Units on Syringe Volume (mL) Protocol Level

โš ๏ธ Always use a new sterile needle and syringe for each injection.

โš ๏ธ Safety & Precautions

Ipamorelin is generally well-tolerated at recommended doses. Compared to other GHRPs, it has a more favorable side-effect profile with minimal cortisol or prolactin elevation. However, comprehensive human safety data is limited.

  • Injection site reactions: Mild redness, tenderness, or pain at injection site
  • Flushing or headache: Occasional and mild
  • Nausea: Rare, especially at higher doses
  • Hunger increase: Some users report mild appetite increase due to ghrelin mimicry

Important Safety Considerations:

  • Ipamorelin is not FDA-approved for any indication
  • Human data is very limited; only the 2009 Phase 1 trial and the 2025 Faccioli study are available
  • The compound was discontinued after Phase 1, making extensive human data scarce
  • Potential for increased hunger (ghrelin mimicry)
  • Do not use if allergic to Ipamorelin or any ingredients
  • Do not use if pregnant or breastfeeding

โš ๏ธ Warning: Ipamorelin is an investigational peptide with limited human safety data. If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.

๐Ÿ“š References

  • Faccioli F, et al. Ipamorelin test in a cohort of women with low IGF-1. Journal of Investigative Medicine. 2025.
  • Connexios Phase 1 Clinical Trial Data. 2009.
  • Growth Hormone Releasing Peptide Treatment in Men Increases Serum Insulin-Like Growth Factor-1 Levels. Journal of Urology. 2016;195(4S).
  • Ipamorelin Research Overview. Peptide Sciences.
  • Ipamorelin Technical Guide. Benchchem.

This information is for educational and research purposes only. Always consult with a qualified healthcare professional.

Last updated: July 2026

โš ๏ธ FOR RESEARCH PURPOSES ONLY